GAITHERSBURG, Md., Dec. 11 /PRNewswire-FirstCall/ -- Iomai Corporation today announced the promotion of Jin-Sook Chung to Vice President of Human Resources from Director of Human Resources and Administration. In her new role, Chung is responsible for all aspects of the human resources function at Iomai, a biotechnology company developing novel, patch-based vaccines.
Chung joined Iomai in 1997, making her one of the longest-serving employees at the company. Before coming to Iomai, she worked at the World Bank's International Finance Corporation. She also has served at a number of multinational companies in Korea, including Hoechst, General Electric, RJ Reynolds and Northwest Airlines. Chung holds an MBA from George Washington University.
"We believe that in the next several years we will experience significant growth at Iomai, and we're fortunate to have a company veteran overseeing the crucial process of building our first-class workforce and perpetuating our innovative culture," said Stanley C. Erck, President and Chief Executive Officer of Iomai. "Jin-Sook is a proven asset to Iomai, and we're thrilled to have her serve as Vice President."
As Iomai has accelerated the preclinical and clinical programs for its vaccine patches -- including initiating new trials for its seasonal influenza and travelers' diarrhea vaccines -- the company's ranks have swelled. Iomai now employs 100, up from 66 at the end of 2005.
About Iomai Corporation
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers' diarrhea. For more information on Iomai, please visit www.iomai.com.
Iomai CorporationCONTACT: Russell P. Wilson, Senior Vice President, Chief Financial Officerand General Counsel, of Iomai Corporation, +1-301-556-4478 orinvestors@iomai.com; or Brian Reid of WeissComm Partners, Inc.,+1-703-402-3626 or breid@weisscommpartners.com, for Iomai Corporation
Web site: http://www.iomai.com/
